Immix Biopharma Inc. has presented its latest advancements in cell therapy for AL Amyloidosis and other serious diseases through its innovative N-GENIUS platform. The company has developed NXC-201, a sterically-optimized CAR-T construct designed to enhance tolerability by reducing non-specific activation through a "digital filter." This pioneering approach aims to provide improved treatment options for patients with relapsed/refractory AL Amyloidosis, which currently has no FDA-approved drugs. Immix has reported promising clinical data from their NEXICART-2 U.S. trial, including an oral presentation of interim results at ASCO 2025. The company highlights a significant market opportunity with a substantial patient prevalence in the U.S. and an established pricing floor for BCMA CAR-T therapies. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.